Cargando…
TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is a non-invasive alternative to surgery to control primary renal cell cancer (RCC) in patients that are medically inoperable or at high-risk of post-surgical dialysis. The objective of the FASTRACK II clinical trial is to investigate the ef...
Autores principales: | Siva, Shankar, Chesson, Brent, Bressel, Mathias, Pryor, David, Higgs, Braden, Reynolds, Hayley M., Hardcastle, Nicholas, Montgomery, Rebecca, Vanneste, Ben, Khoo, Vincent, Ruben, Jeremy, Lau, Eddie, Hofman, Michael S., De Abreu Lourenco, Richard, Sridharan, Swetha, Brook, Nicholas R., Martin, Jarad, Lawrentschuk, Nathan, Kron, Tomas, Foroudi, Farshad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199711/ https://www.ncbi.nlm.nih.gov/pubmed/30352550 http://dx.doi.org/10.1186/s12885-018-4916-2 |
Ejemplares similares
-
Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
por: Hardcastle, Nicholas, et al.
Publicado: (2021) -
A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)
por: Siva, Shankar, et al.
Publicado: (2016) -
Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring
por: Lee, Yoo Young Dominique, et al.
Publicado: (2021) -
A retrospective review of the long-term outcomes of online adaptive radiation therapy and conventional radiation therapy for muscle invasive bladder cancer
por: Yeh, Janice, et al.
Publicado: (2021) -
Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial (99m)Tc-DMSA SPECT/CT
por: Jackson, Price, et al.
Publicado: (2014)